Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ubidecarenone in Metabolic Dysfunction Associated Steatohepatitis: NCT05731596 Clinical Landscape Report 2026
15 October 2026
NCT05731596 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Rencofilstat in Metabolic Dysfunction Associated Steatohepatitis: NCT05737433 Clinical Landscape Report 2026
15 October 2026
NCT05737433 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Telitacicept in Myasthenia Gravis: NCT05737160 Clinical Landscape Report 2026
15 October 2026
NCT05737160 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Beta-Thalassemia: NCT05736419 Clinical Landscape Report 2026
15 October 2026
NCT05736419 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tirzepatide in Diabetes Mellitus, Type 2: NCT05751720 Clinical Landscape Report 2026
15 October 2026
NCT05751720 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Semaglutide (Novo Nordisk) in Metabolic Dysfunction Associated Steatohepatitis: NCT05766709 Clinical Landscape Report 2026
15 October 2026
NCT05766709 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Mitapivat in Thalassemia: NCT05777993 Clinical Landscape Report 2026
15 October 2026
NCT05777993 clinical landscape for Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dapagliflozin in Metabolic Dysfunction Associated Steatohepatitis: NCT05782972 Clinical Landscape Report 2026
15 October 2026
NCT05782972 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
L-Citrulline in Metabolic Dysfunction Associated Steatohepatitis: NCT05778266 Clinical Landscape Report 2026
15 October 2026
NCT05778266 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Hydroxycarbamide in Hemoglobin SC Disease: CTRI/2023/03/051032 Clinical Landscape Report 2026
15 October 2026
CTRI/2023/03/051032 clinical landscape for Hemoglobin SC Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mutated alpha-1 antitrypsi(ApcinteX) in Hemophilia B: NCT05789524 Clinical Landscape Report 2026
15 October 2026
NCT05789524 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GH509 in Metabolic Dysfunction Associated Steatohepatitis: NCT05784779 Clinical Landscape Report 2026
15 October 2026
NCT05784779 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…